R F Pass
Overview
Explore the profile of R F Pass including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
2890
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Temple R, Pass R, Boll T
J Dev Behav Pediatr
. 2001 Jan;
21(6):417-22.
PMID: 11132792
Congenital cytomegalovirus (CMV) infection has an affinity for the central nervous system and has been implicated in a variety of neurological impairments. Analysis of cognitive functioning in children with asymptomatic...
2.
Dahle A, Fowler K, Wright J, Boppana S, Britt W, Pass R
J Am Acad Audiol
. 2000 May;
11(5):283-90.
PMID: 10821506
This investigation consisted of a longitudinal study of the effects of congenital cytomegalovirus (CMV) infection on hearing sensitivity in 860 children with documented asymptomatic or symptomatic congenital CMV infection. Of...
3.
Frey S, Harrison C, Pass R, Yang E, Boken D, Sekulovich R, et al.
J Infect Dis
. 1999 Oct;
180(5):1700-3.
PMID: 10515836
The purpose of this phase I study was to evaluate the safety and immunogenicity of 2 doses of cytomegalovirus glycoprotein B (CMV gB)/MF59 vaccine at 3 different immunization schedules. Ninety-five...
4.
Pass R, Duliege A, Boppana S, Sekulovich R, Percell S, Britt W, et al.
J Infect Dis
. 1999 Sep;
180(4):970-5.
PMID: 10479120
A phase I randomized, double-blind, placebo-controlled trial was done with a cytomegalovirus (CMV) vaccine based on the envelope glycoprotein, gB, combined with a novel adjuvant, MF59. Participants received CMV gB...
5.
Zanghellini F, Boppana S, Emery V, Griffiths P, Pass R
J Infect Dis
. 1999 Aug;
180(3):702-7.
PMID: 10438357
We followed 45 seronegative adolescents for acquisition of cytomegalovirus (CMV); 6 (5 female, 1 male) seroconverted after a median of 7.5 months. All were free of signs and symptoms. CMV...
6.
Fowler K, Dahle A, Boppana S, Pass R
J Pediatr
. 1999 Jul;
135(1):60-4.
PMID: 10393605
Objective: To predict whether universal newborn auditory screening will identify most infants with sensorineural hearing loss (SNHL) caused by congenital cytomegalovirus (CMV) infection. Study Design: A cohort of 388 children...
7.
Boppana S, Fowler K, Britt W, Stagno S, Pass R
Pediatrics
. 1999 Jul;
104(1 Pt 1):55-60.
PMID: 10390260
Objectives: To determine the frequency of symptomatic congenital cytomegalovirus (CMV) infection in the offspring of women with a recurrent maternal CMV infection and to characterize the demographic and newborn findings....
8.
Kashden J, Frison S, Fowler K, Pass R, Boll T
J Dev Behav Pediatr
. 1998 Aug;
19(4):254-9.
PMID: 9717134
The findings of previous studies examining the neurocognitive development of children with clinically inapparent (asymptomatic) cytomegalovirus (CMV) infection have demonstrated mixed results. These studies have generally depended on small sample...
9.
10.
Whitley R, Cloud G, Gruber W, Storch G, Demmler G, Jacobs R, et al.
J Infect Dis
. 1997 May;
175(5):1080-6.
PMID: 9129069
Congenital cytomegalovirus (CMV) infection occurs in approximately 1% of newborns in the United States. A phase II evaluation was done of ganciclovir for the treatment of symptomatic congenital CMV infection....